Management of Padcev (Enfortumab Vedotin) Extravasation
If Padcev extravasation occurs, immediately stop the infusion, leave the cannula in place, attempt gentle aspiration of residual drug through the existing line, then remove the catheter and apply dry cold compresses for 15-20 minutes four times daily for 1-2 days while closely monitoring for delayed reactions that may worsen over 2-7 days. 1
Immediate Actions (First 10 Minutes)
The FDA label for Padcev explicitly warns that extravasation can cause delayed skin and soft tissue reactions, with symptoms potentially worsening for 2-7 days before resolving over 1-4 weeks 1. Do not apply manual pressure to the extravasation site as this may worsen tissue damage 2.
Step-by-Step Protocol:
- Stop the infusion immediately upon suspicion of extravasation
- Leave the IV cannula in place and attempt to gently aspirate as much extravasated solution as possible through the existing line 2
- Remove the cannula after aspiration attempt
- Apply dry cold compresses (not ice directly on skin) for 15-20 minutes, four times daily for 24-48 hours 2, 3
- Elevate the affected limb 2
- Administer analgesia as needed 2
Critical Monitoring Requirements
Padcev extravasation reactions are characteristically delayed, with erythema, swelling, increased temperature, and pain worsening until 2-7 days post-extravasation 1. In clinical trials, 1% of patients experienced skin and soft tissue reactions, with 0.3% developing Grade 3-4 reactions including cellulitis, bullae, or exfoliation 1.
Monitor patients closely for:
- Progressive erythema and swelling (days 2-7)
- Development of bullae or blistering
- Signs of secondary cellulitis
- Tissue necrosis (rare but possible)
No Specific Antidote Available
Unlike anthracycline extravasations (which have dexrazoxane) or mechlorethamine (which has sodium thiosulfate), there is no FDA-approved specific antidote for Padcev extravasation 2. The general chemotherapy extravasation guidelines do not address antibody-drug conjugates specifically, as these are newer agents 2.
What NOT to Do:
- Do not use subcutaneous corticosteroids - evidence shows they may increase the need for surgical debridement (46% vs 13% without corticosteroids) 2
- Do not apply DMSO - this is only indicated for anthracyclines, mitomycin C, or platinum salts 2
- Do not use warm compresses - cold therapy is appropriate for Padcev 2
When to Escalate Care
Consider surgical consultation if:
- Pain persists beyond 10 days 2
- Progressive tissue necrosis develops
- Bullae or exfoliation occurs (reported in 0.3% of cases) 1
- Secondary cellulitis develops requiring antibiotics 4
Surgical management, if needed, should consist of wide three-dimensional excision of involved tissue with delayed split-thickness skin grafting at 2-3 days 2, 5.
Prevention is Key
Ensure adequate venous access before starting Padcev and monitor the infusion site continuously during administration 1. The FDA label emphasizes this as a critical preventive measure. Consider using central venous access for patients with poor peripheral venous access, though central line extravasation (while rare at 0.24%) can be more serious 2.
Documentation Requirements
Thoroughly document every extravasation incident 2:
- Patient identification
- Date and time of extravasation
- Drug name and estimated volume extravasated
- Signs and symptoms (patient-reported and observed)
- IV access description and location
- Management steps taken with timestamps
- Photographic documentation is strongly recommended for follow-up and decision-making 2
Return to Treatment
Case reports demonstrate that patients who experienced Padcev extravasation with conservative management (including treatment of secondary cellulitis when present) were able to resume Padcev treatment without subsequent adverse events 4. However, ensure complete resolution of the extravasation injury before restarting therapy and consider using alternative venous access.
Clinical Context
Real-world data shows Padcev is generally well-tolerated with manageable toxicity profiles 6, 7, 8, but extravasation remains a recognized complication requiring vigilant monitoring. The delayed nature of Padcev extravasation reactions distinguishes it from many traditional chemotherapy agents and necessitates patient education about seeking care if symptoms develop or worsen in the days following infusion.